BWX Technologies Reports Record Third Quarter 2019 Results; Increases Full-Year 2019 Non-GAAP EPS Guidance
LYNCHBURG, Va.-(BUSINESS WIRE)-BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported third quarter 2019 revenue of $506 million, a new quarterly record for the Company and an 18.9% increase compared with $426 million in the third quarter of 2018. GAAP net income for the third quarter 2019 was $74.8 million, or $0.78 per diluted share, compared with GAAP net income of $77.9 million, or $0.78 per diluted share, in the prior-year period. Non-GAAP net income for the third quarter 2019 was $75.3 million, or $0.79 per diluted share, compared with non-GAAP net income of $40.1 million, or $0.40 per diluted share, in the prior-year period. A reconciliation of non-GAAP results is detailed in Exhibit 1.
BWXT Awarded $806 Million Long-Lead Material Contract in Support of Naval Reactors Manufacturing
(LYNCHBURG, Va. – Oct. 17, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that the U.S. Naval Nuclear Propulsion Program has awarded subsidiary BWXT Nuclear Operations Group, Inc. a contract with options totaling approximately $806 million for the procurement of long-lead materials required for the manufacture of naval reactor components.
BWXT to Restart Existing TRISO Nuclear Fuel Production Line and Expand Capacity
BWX Technologies, Inc. (NYSE: BWXT) announced today that it is in the process of restarting its existing TRISO nuclear fuel production line and is planning to expand its existing capacity within approximately 12 months.
BWXT Announces Availability of FDA-Approved Indium In-111 Oxyquinoline Solution
(LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.
BWX Technologies Reports Second Quarter 2019 Results With Solid Revenue and EPS Growth
Lynchburg, VA - August 5, 2019 - BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2019 revenue of $471 million, a 7.4% increase compared with $439 million in the second quarter of 2018. GAAP net income for the second quarter 2019 was $58.9 million, or $0.62 per diluted share, compared with GAAP net income of $60.7, or $0.60 per diluted share, in the prior-year period. Non-GAAP net income for the second quarter 2019 was $59.1 million, or $0.62 per diluted share, compared with non-GAAP net income of $58.0 million, or $0.58 per diluted share, in the prior-year period. A reconciliation of non-GAAP results is detailed in Exhibit 1.
BWXT Names Leland D. Melvin to Board of Directors
Melvin spent more than 24 years with NASA as an astronaut, research engineer and administrator. He served twice on board the space shuttle Atlantis as a mission specialist to support the International Space Station. In addition, Melvin served as NASA’s associate administrator for education until he retired in 2014.
BWXT Reports First Quarter 2019 Results with Record Backlog
BWX Technologies, Inc. (NYSE: BWXT) reported first quarter 2019 revenue of $416 million.
BWXT to Participate in Bank of America Merrill Lynch Global Industrials Conference
BWX Technologies, Inc. (NYSE:BWXT) announced today that it will participate in the 2019 Bank of America Merrill Lynch Global Industrials Conference in London.
